A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Rucaparib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Dec 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
- 24 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Oct 2018.